Cancer treatment and research communications最新文献

{"title":"Erratum to: \"Rectal cancer survival and prognostic factors in Iranian population: A retrospective cohort study\" [Cancer Treatment and Research Communications Volume 39, 2024, 100810].","authors":"Seyed Kazem Mirinezhad, Mostafa Akbarzadeh-Khiavi, Farshad Seyednejad, Mohammad Hossein Somi","doi":"10.1016/j.ctarc.2025.100916","DOIUrl":"https://doi.org/10.1016/j.ctarc.2025.100916","url":null,"abstract":"","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":" ","pages":"100916"},"PeriodicalIF":0.0,"publicationDate":"2025-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143810524","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effectiveness of problem-solving skills training on the self-efficacy and self-concept of the adolescent with cancer","authors":"Ali Askari ,&nbsp;Seyedeh Zahra Aemmi ,&nbsp;Hamidreza Behnam Vashani","doi":"10.1016/j.ctarc.2025.100919","DOIUrl":"10.1016/j.ctarc.2025.100919","url":null,"abstract":"<div><h3>Objective</h3><div>Self-efficacy and self-concept can be negatively affected by developmental crises (such as the onset of adolescence) and acquired crises (such as disease). This study aimed to assess the effectiveness of problem-solving skills training on the self-efficacy and self-concept of adolescents diagnosed with cancer.</div></div><div><h3>Methods</h3><div>This randomized clinical trial involved 60 adolescents with cancer at Dr. Sheikh hospital in Mashhad. The intervention group participated in seven sessions of problem-solving skills training. Adolescents in two groups (intervention = 30 and routine care = 30) completed the Muris self-efficacy questionnaire and Piers-Harris self-concept scale at baseline and one month later.</div></div><div><h3>Results</h3><div>The findings revealed significant differences in the changes in self-efficacy and self-concept scores between the two groups after the intervention (p &lt; 0.001). The improvement in self-efficacy and self-concept scores in the intervention group was statistically significant.</div></div><div><h3>Conclusion</h3><div>Problem-solving skills training can enhance self-efficacy and self-concept, thereby improving the mental health of adolescents with cancer by fostering empowerment, increasing positive mood, and enhancing cognitive understanding of their challenges. Nurses can implement this training as a straightforward and cost-effective supportive care strategy for adolescents affected by cancer.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"43 ","pages":"Article 100919"},"PeriodicalIF":0.0,"publicationDate":"2025-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143821190","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Oncological outcomes and locoregional recurrence after fluorescence guided surgery for axillary staging in early breast cancer: A single UK center experience","authors":"Rahul Kanitkar ,&nbsp;Vassilis Pitsinis ,&nbsp;Bushra Riaz ,&nbsp;Alessio Vinci ,&nbsp;Fiona Hogg ,&nbsp;Lee B. Jordan","doi":"10.1016/j.ctarc.2025.100922","DOIUrl":"10.1016/j.ctarc.2025.100922","url":null,"abstract":"<div><div>Sentinel lymph node biopsy (SLNB) is an established standard technique for staging the axilla in clinically node-negative breast cancer patients. This study evaluates the efficacy of a dual tracer technique combining Indocyanine Green (ICG) fluorescence and blue dye for SLNB in early breast cancer patients at a single institution (Perth Royal Infirmary, Scotland). Over an eight-month period, 139 patients with clinically node-negative invasive breast cancer underwent SLNB, achieving a sentinel lymph node identification rate of 98.5%. Among the identified nodes, a node positivity rate of 19.7% was observed. With a median follow-up of 42 months, axillary recurrence was recorded in only 0.9% of patients, alongside local and distant recurrences of 1.8% and 5.5%, respectively. The findings suggest that the ICG and blue dye technique maintains a low axillary recurrence rate comparable to traditional methods, while also addressing logistical challenges posed by the COVID-19 pandemic. This technique offers a promising alternative to radioisotope-based methods and opens new possible routes for non-radioactive axillary staging techniques. Further long-term outcomes are anticipated as the use of ICG as a sole tracer is integrated into routine practice.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"43 ","pages":"Article 100922"},"PeriodicalIF":0.0,"publicationDate":"2025-04-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143776821","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognosis and clinical outcome of papilloma neoplasm of the breast: An observational study","authors":"Puttiporn Naowaset","doi":"10.1016/j.ctarc.2025.100900","DOIUrl":"10.1016/j.ctarc.2025.100900","url":null,"abstract":"<div><h3>Objective</h3><div>due to rarity of this subtype, the aim of this study was to investigate the clinicopathological features, treatment, and prognosis of papillary carcinoma of the breast.</div></div><div><h3>Materials and methods</h3><div>The histopathologic reports of all papillary breast lesion from January 1, 2010, to January 31, 2020, at Ramathibodi hospital were retrieved, comprising a total of 544 reports. Of the 133 (24.44%) histopathologically proved papillary lesions, 411 (75.55%) lesions were excluded from this study due to mixed histopathologic type. The clinical characteristics including age, menopausal status, clinical presentation, the presence of mass, presence of suspicious calcification were recorded. Diagnostic and tumor characteristics including immunohistochemistry, Nottingham grade of tumor, pathological stage were recorded. Local and systemic treatment including type of surgery, chemotherapy, radiation therapy, anti-hormonal therapy and targeted therapy were recorded. Prognosis including overall and disease-free survival were recorded.</div></div><div><h3>Results</h3><div>Of 133 papillary lesions, 47 lesions were invasive solid papillary carcinoma, 7 lesions were invasive encapsulated papillary carcinoma, 31 lesions were solid papillary carcinoma, 27 lesions were encapsulated papillary carcinoma, 16 lesions were invasive papillary carcinoma, and 5 lesions were intraductal papillary carcinoma. The mean follow-up period was 64 months, during which we identified 6 cases of recurrence. Additionally, non-cancer-related deaths were observed in 2 patients. There was no significant difference in disease free survival (DFS) among all types, with a rate of 95.49%. Similarly, overall survival (OS) showed no significant difference, with a rate of 98.5%</div></div><div><h3>Conclusion</h3><div>Papillary carcinoma is a rare variant of breast tumor. All papillary carcinomas, including the invasive types, exhibit an excellent prognosis. It is suggested that invasive papillary carcinoma should be considered a subtype with a favorable prognosis, allowing for minimization of treatment accordingly.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"43 ","pages":"Article 100900"},"PeriodicalIF":0.0,"publicationDate":"2025-03-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143821189","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"WITHDRAWN: Association between Prostatic Calculi and Prostate Cancer.","authors":"Yaqin Fan, Yang Luan, Liangyong Zhu, Tianbao Huang, Xuefei Ding, Chaoqun Shi, Fei Wang","doi":"10.1016/j.ctarc.2025.100873","DOIUrl":"https://doi.org/10.1016/j.ctarc.2025.100873","url":null,"abstract":"<p><p>This article has been withdrawn at the request of the author(s) and/or editor. The Publisher apologizes for any inconvenience this may cause. The full Elsevier Policy on Article Withdrawal can be found at https://www.elsevier.com/about/policies/article-withdrawal.</p>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":" ","pages":"100873"},"PeriodicalIF":0.0,"publicationDate":"2025-01-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143656154","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of recurrence and survival in multifocal versus unifocal breast cancer patients at a tertiary center: A case-control study","authors":"Mania Beiranvand,&nbsp;Atieh Akbari,&nbsp;Mohamad Esmaeil Akbari","doi":"10.1016/j.ctarc.2025.100894","DOIUrl":"10.1016/j.ctarc.2025.100894","url":null,"abstract":"<div><h3>Purpose</h3><div>Breast cancer, a significant contributor to global cancer incidence, presents varying clinical and pathological profiles. This study aimed to compare clinical and pathological characteristics, survival rates, and recurrence patterns between patients with multifocal (MF) and unifocal (UF) breast cancer who underwent breast-conserving surgery, to identify potential differences that could inform clinical management and treatment strategies.</div></div><div><h3>Methods</h3><div>The study was a retrospective case-control analysis. Patient records from 2006 to 2015 at the Breast Cancer Research Center of Shahid Beheshti University of Medical Sciences were examined. Inclusion criteria encompassed informed consent, stage I-III breast cancer diagnosis, and breast-conserving surgery. Neoadjuvant chemotherapy recipients, patients with incomplete records, and those with treatment non-compliance were excluded. Demographic data, clinical parameters, and pathological findings were collected and analyzed. Patients were categorized into MF and UF groups based on tumor nodule count. Survival and recurrence rates were assessed using Kaplan-Meier analysis and the Log-Rank test.</div></div><div><h3>Results</h3><div>While mean age did not significantly differ between MF (47.36 years) and UF (49.97 years) breast cancer patients, a significant disparity in menarche age was observed (MF: 13.14 years vs. UF: 12.98 years, <em>p</em>= 0.03). Tumor size significantly varied (MF: 3.68 cm vs. UF: 3.21 cm, <em>p</em>= 0.01). However, menopausal status, hormone receptor (ER and PR) status, mortality, in vitro fertilization history, breastfeeding history, recurrence rates, HER2 status, and pathologic grade showed no significant differences between groups. The 5-year overall survival (OS) rates were 89.2 % for MF and 90.5 % for UF (<em>p</em>= 0.45), and the 5-year recurrence-free survival (RFS) rates were 84.7 % for MF and 86.1 % for UF (<em>p</em>= 0.52).</div></div><div><h3>Conclusion</h3><div>This study suggests that multifocal breast cancer is associated with earlier menarche and larger tumor size compared to unifocal breast cancer. Other clinical and pathological parameters, as well as survival and recurrence rates, did not significantly differ between these two groups. These findings highlight the importance of considering multifocality in clinical decision-making, particularly about tumor size and menarche age, while reassuring that survival and recurrence outcomes remain comparable between MF and UF breast cancer patients.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"43 ","pages":"Article 100894"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143641668","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The impact of multiple neoadjuvant chemotherapy cycles in patients with advanced epithelial ovarian cancer: A single center experience","authors":"Wala Mehros ,&nbsp;Rowayd Gobouri ,&nbsp;Omar Turkistani ,&nbsp;Abdulaziz Hinnawi ,&nbsp;Omar Alahmary ,&nbsp;Ahmed Shams ,&nbsp;Jaser Tashkandi ,&nbsp;Amal Al Somairi ,&nbsp;Amal Hanjour ,&nbsp;Syed Sameer Aga ,&nbsp;Hatim Al-Jifree","doi":"10.1016/j.ctarc.2025.100904","DOIUrl":"10.1016/j.ctarc.2025.100904","url":null,"abstract":"<div><h3>Aim</h3><div>Three to four cycles of neoadjuvant chemotherapy prior to interval debulking surgery is a common treatment of ovarian cancer. This study aimed to determine the impact of increasing the number of neoadjuvant chemotherapy cycles on overall survival), progression-free survival, and disease responses in patients diagnosed with epithelial ovarian cancer.</div></div><div><h3>Methods</h3><div>Twenty-eight patients who underwent NACT for advanced-stage EOC were enrolled in a retrospective cohort study conducted at Princess Noorah Oncology Center and King Abdulaziz Medical City between 2010 and 2021 and divided into two groups. Patients in the first group received fewer than six cycles of NACT while those the second group were treated with six or more cycles. Differences in the OS, PFS, and NACT responses were compared.</div></div><div><h3>Results</h3><div>The median OS was 22.50 months ([IQR], 35.75 months) among patients in the group who received fewer than six cycles of NACT and 29.5 months (IQR, 28.75 months) for those treated with six cycles or more (<em>P</em> = 0.67). The median PFS was 12 months (IQR, 16) for the group that received fewer than six cycles, and nine months (IQR, 21.5 months) for patients assigned to the group that received six or more cycles (<em>P</em> = 0.88). Six of the patients from the group that received fewer than six cycles of NACT and five of the patients from the group that received six cycles or more achieved a complete response to therapy (<em>P</em> = 0.81).</div></div><div><h3>Conclusion</h3><div>Increasing the number of NACT cycles did not significantly impact OS, PFS, or the overall response to therapy. However, the study's small patient population presents a limitation.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"43 ","pages":"Article 100904"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143869411","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring the prognostic significance of vitamin D deficiency in pancreatic cancer: Disease progression and survival outcomes","authors":"Aladeen Alloubani,&nbsp;Baraa Abadalhaq,&nbsp;Amal Alshami,&nbsp;Diana Fakhory,&nbsp;Feras Abdalghani,&nbsp;Mallak Almasri,&nbsp;Maysa Alkouz","doi":"10.1016/j.ctarc.2025.100917","DOIUrl":"10.1016/j.ctarc.2025.100917","url":null,"abstract":"<div><h3>Background</h3><div>Pancreatic cancer remains one of the most aggressive malignancies with limited treatment options and poor survival rates. Vitamin D deficiency has been suggested to influence cancer progression and survival outcomes in various malignancies.</div></div><div><h3>Aim</h3><div>This study aimed to investigate the association between Vitamin D deficiency and disease progression as well as survival in patients diagnosed with pancreatic cancer.</div></div><div><h3>Methods</h3><div>A retrospective cohort study was conducted, including 151 patients diagnosed with pancreatic cancer between 2012 and 2022. Serum Vitamin D levels at the time of diagnosis were measured. Disease progression was evaluated through radiological assessments and clinical reports. Survival outcomes, including overall survival (OS) and progression-free survival (PFS), were analyzed using Kaplan-Meier survival curves and Cox proportional hazards regression models.</div></div><div><h3>Results</h3><div>Of the 151 patients, 84 (56 %) were identified as Vitamin D deficient at the time of diagnosis. The deficient group exhibited a significantly higher frequency of advanced-stage disease (stages III and IV) compared to the non-deficient group (<em>p</em> &lt; 0.05). During the follow-up period, 66 (78.6 %) of Vitamin <span>d</span>-deficient patients and 56 (84.8 %) of non-deficient patients experienced disease progression (<em>p</em> = 0.51). Moreover, Kaplan-Meier analysis showed a non-significant trend toward shorter median PFS (8.95 months vs. 9.27 months, <em>p</em> = 0.51) and OS (17.64 months vs. 19.05 months, <em>p</em> = 0.616) in the Vitamin <span>d</span>-deficient group.</div></div><div><h3>Conclusion</h3><div>Vitamin D deficiency is prevalent among patients with pancreatic cancer and appears to be associated with more advanced disease at diagnosis. Although a trend toward poorer survival outcomes was observed, the association between Vitamin D deficiency and OS/PFS did not reach statistical significance. Additional prospective studies are needed to confirm these findings and explore potential benefits of Vitamin D supplementation in pancreatic cancer management.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"43 ","pages":"Article 100917"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143821500","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and safety of zanubrutinib combined with chimeric antigen receptor T-cell therapy targeting CD19 in refractory or relapsed diffuse large B cell lymphoma: A retrospective analysis","authors":"Jinhuan Xu ,&nbsp;Xiaoying Zhang ,&nbsp;Yun Li ,&nbsp;Fankai Meng ,&nbsp;Yicheng Zhang ,&nbsp;Miao Zheng","doi":"10.1016/j.ctarc.2025.100902","DOIUrl":"10.1016/j.ctarc.2025.100902","url":null,"abstract":"<div><h3>Background</h3><div>While chimeric antigen receptor T-cell (CAR T) therapy has shown promise in treating B-cell non-Hodgkin lymphoma, its efficacy is variable in patients with poor initial responses. This study investigates the efficacy and safety of zanubrutinib combined with CAR T therapy targeting CD19 in refractory/relapsed diffuse large B cell lymphoma (DLBCL).</div></div><div><h3>Methods</h3><div>We conducted a retrospective study of 17 patients with R/R DLBCL who received zanubrutinib combined with anti-CD19 CAR T-cell therapy. We assessed overall survival (OS) and progression-free survival (PFS) and conducted subgroup analyses. We also monitored CAR T-cell expansion by quantifying vector copy numbers (VCN). Safety and tolerability were assessed by documenting adverse events, including cytokine release syndrome and neurotoxicity.</div></div><div><h3>Results</h3><div>The median follow-up was 30 months (range, 4–36). The overall response rate(ORR) was 88.2 %, with 70.5 % achieving complete remission. At 24 months, the estimated PFS was 59 % (95 %CI, 40–88 %), and the OS was 71 % (95 %CI, 52–90 %). At 36 months, the estimated OS was 65 % (95 %CI, 46–92 %). Patients with non-elevated lactate dehydrogenase(LDH) levels showed a higher PFS probability (100 %) compared to those with elevated LDH (42 %, 95 %CI: 21 %-81 %) (log-rank, <em>p</em> = 0.071). The area under the receiver-operating characteristic (ROC) curve for peak CAR T-cell expansion was 0.773, suggesting an optimal cutoff at day 13 for enhancing survival (sensitivity 66.7 %, specificity 90.9 %; <em>p</em> = 0.07). Early peak expansion (before day 13) correlated with better PFS and OS (log-rank, <em>p</em> = 0.0018 and <em>p</em> = 0.0053, respectively). The total VCN AUC was 0.636, with a cutoff of 12,690 significantly predicting survival (sensitivity 83.3 %, specificity 72.7 %; <em>p</em> = 0.366). Kaplan-Meier analysis indicated statistically significant differences in OS for patients with VCN below 12,690 (log-rank, <em>p</em> = 0.017) in comparison to those exceeding 12,690, though trends in PFS did not reach statistical significance (log-rank, <em>p</em> = 0.12). Safety profiles indicated manageable cytokine release syndrome, with no severe neurotoxicity reported.</div></div><div><h3>Conclusions</h3><div>Zanubrutinib combined with CAR T-cell therapy offers an effective treatment option for patients with R/R DLBCL, enhancing response rates and survival. Detailed analysis of CAR T-cell expansion provides insight into the dynamics of cellular responses, underscoring the potential for tailored therapeutic approaches based on biological markers.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"43 ","pages":"Article 100902"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143725012","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Carfilzomib in relapsed/refractory multiple myeloma patients – real world evidence – experiences of the Croatian cooperative group for hematologic diseases (KROHEM)","authors":"Davor Galusic ,&nbsp;Josip Batinic ,&nbsp;Ivan Krecak ,&nbsp;Barbara Dreta ,&nbsp;Delfa Radic Kristo ,&nbsp;Mario Pirsic ,&nbsp;Goran Rincic ,&nbsp;Jasminka Sincic-Petricevic ,&nbsp;Toni Valkovic ,&nbsp;Milan Vujcic ,&nbsp;Marin Simunic ,&nbsp;Karla Misura Jakobac ,&nbsp;Martina Sedinic Lacko ,&nbsp;Klara Brcic ,&nbsp;Vlatka Perisa ,&nbsp;Fran Petricevic ,&nbsp;Dragana Grohovac ,&nbsp;Hrvoje Holik ,&nbsp;Martina Moric Peric ,&nbsp;Ivan Zekanovic ,&nbsp;Sandra Basic-Kinda","doi":"10.1016/j.ctarc.2025.100912","DOIUrl":"10.1016/j.ctarc.2025.100912","url":null,"abstract":"<div><h3>Background</h3><div>Carfilzomib-based regimens brought a significant improvement in the treatment of relapsed/refractory multiple myeloma (RRMM). Even though efficacy and safety profiles of carfilzomib are well-established in several clinical trials, there is limited real-world data with carfilzomib-based protocols. Here we present our real-world experience with carfilzomib-based regimens for treatment of patients with RRMM in Croatia.</div></div><div><h3>Methods</h3><div>Data on patients with RRMM starting carfilzomib-based protocols in the period between June 2019 and February 2023 was collected by retrospective chart review from 14 Croatian centres.</div></div><div><h3>Results</h3><div>A total of 119 patients with RRMM were included; median age was 66 years (range 45–83 years), 59 (49.6 %) were females, and the median number of previous lines of therapies was 2 (range 1–8). Triplet based regimen was treatment choice in 84 (70.6 %) and 35 (29.4 %) patients were treated with carfilzomib in combination with dexamethasone (Kd). Overall response rate was 61.7 %, with 20 patients (18.7 %) achieving complete response (CR). Median progression free survival (PFS) and overall survival (OS) for entire cohort were 9.4 and 13.2 months, respectively. Median PFS was 12.8 months and 4.1 months for the triplets and doublets, respectively; the corresponding median OS was 18.6 and 7.9 months, respectively. The most common adverse events were anemia and thrombocytopenia; 19 patients (16 %) experienced cardiovascular events.</div></div><div><h3>Conclusion</h3><div>This is the first study to analyze clinical outcomes of RRMM patients treated with carfilzomib-based regimens in Croatia. Carfilzomib-based regimens showed substantial efficacy and acceptable toxicity in RRMM, especially in earlier treatment lines and triplet combinations.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"43 ","pages":"Article 100912"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143705713","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}